JNJ as reported
Johnson & Johnson reported $97.9B of revenue over the trailing twelve months, +8.1% on the year before. 11 reported series are charted on this page, each one as filed.
$97.9B
Revenue, trailing twelve months · to Q2 2026 · +8.1% against the twelve months before
- Net Income
- $21.0B
Net Income · −7.2% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- $22.2B
Free Cash Flow · +20% year on year · trailing twelve months to Q2 2026
- EPS
- $8.62
EPS · −7.8% year on year · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $97.9B | +8.1% | Q2 2026 |
| Net Income | $21.0B | −7.2% | Q2 2026 |
| EPS | $8.62 | −7.8% | Q2 2026 |
| Gross Margin | 68% | n/a | Q2 2026 |
| Op Margin | 30% | n/a | Q1 2015 · 45 quarters behind |
| Net Margin | 21% | n/a | Q2 2026 |
| ROE | 29% | n/a | Q2 2026 |
| ROA | 12% | n/a | Q2 2026 |
| ROIC | 28% | n/a | Q1 2015 · 45 quarters behind |
| Free Cash Flow | $22.2B | +20% | Q2 2026 |
| P/E | 31.3 | n/a | today |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Johnson & Johnson (JNJ) - Revenue & ProfitRevenue & ProfitJohnson & Johnson (JNJ)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Drug Manufacturers - General
Ranks #2 of 16 by Smart Score